KalVista Pharmaceuticals (KALV) Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis
Get Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in patients receiving long-term prophylaxis (LTP) treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (APAAACI) in Singapore.
A systematic literature review of interventional and observational LTP studies revealed that although LTP yields significant reductions in HAE attack frequency, many patients continue to experience attacks in all anatomic locations, including potentially life-threatening laryngeal attacks. In randomized controlled trials, long-term (≥6 months) attack-free rates are low (<45%) with pdC1-INH, berotralstat, danazol, and tranexamic acid, and are generally higher with lanadelumab (44% for lanadelumab 300 mg Q2W [77% in a post hoc analysis from Day 70 to Day 182]).
“As highlighted in HAE clinical practice guidelines, the goal of LTP is to achieve full control of disease burden. However, this systematic review of LTP treatment studies shows that attack-free rates are lower than perceived, and therefore, substantial disease burden remains for many people living with HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Access to safe and effective on-demand therapy is essential for all people living with HAE, including those receiving LTP. Sebetralstat, an oral plasma kallikrein inhibitor in late-stage development for on-demand treatment of HAE attacks, has the potential to address this persisting unmet need.”
The following presentations occurred at APAAACI 2023:
- Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review: Hilary J. Longhurst, Auckland City Hospital, Te Toka Tumai, and University of Auckland, Auckland, New Zealand
- KONFIDENT Phase 3 Trial Global Expansion: Sebetralstat Pharmacokinetics and Pharmacodynamics in Japanese and Chinese Adults: Daisuke Honda, Chiba University Graduate School of Medicine, Chiba, Japan
Links to all posters and presentations can be found on the KalVista website under “Publications”.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Masimo Corp. (MASI) Issues Response to "Latest Politan Fictions"
- Lucid Diagnostics (LUCD) Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Popula
- Scinai Immunotherapeutics (SCNI) Publishes Q1 2024 Financial Results and Provides Business Update
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!